{"content":[{"text":"INCREASED REMOVAL RATES OF FLUID AND SODIUM DURING STEADY \n CONCENTRATION PERITONEAL DIALYSIS COMPARED TO ICODEXTRIN AND \n PERITONEAL EQUILIBRATION TEST","bbox":{"left":0.095142,"top":0.109481,"width":0.7662439999999999,"height":0.05155399999999999}},{"text":"Carlsson O1, Heimbürger O3, Johansson A-C2, Martus G4, Wilkie M5, Hegbrant J6, Johansson \n A1, De Leon C1","bbox":{"left":0.095142,"top":0.178181,"width":0.8093919999999999,"height":0.03444999999999998}},{"text":"1. Triomed AB, Lund, Sweden. \n 2. Department of Nephrology, Skåne University Hospital, Malmö, Sweden. \n 3. CLINTEC, Karolinska Institute, Karolinska University Hospital, Solna, Sweden. \n 4. Department of Nephrology, Skåne University Hospital, Lund, Sweden. \n 5. Department of Nephrology, Sheffield Teaching Hospitals National Health Service \n Foundation Trust, Sheffield, United Kingdom. \n 6. Department of Nephrology, Lund University, Lund, Sweden.","bbox":{"left":0.095142,"top":0.22992,"width":0.735884,"height":0.12043199999999998}},{"text":"Background and Aims \n Removal of fluid and sodium may be a major challenge in PD, which can be addressed \n using icodextrin for the long dwells. Steady concentration PD (SCPD) with Carry Life® UF \n is a novel treatment modality where the intraperitoneal glucose concentration can be kept \n stable throughout the treatment maintaining ultrafiltration and sodium removal. This is \n performed by transferring a small volume of the dialysate into the device, where glucose is \n added and the dialysate returned to the patient. The present study was performed to \n compare the effect of SCPD with icodextrin and peritoneal equilibration test (PET) on \n ultrafiltration and sodium removal.","bbox":{"left":0.095142,"top":0.393296,"width":0.809037,"height":0.16201600000000005}},{"text":"Method \n Eight stable PD patients (high or high average transporters) were included in the study. \n Subjects were treated with three 5-hour Carry Life UF treatments using three different \n glucose doses (11, 14, 20 g/h). An initial fill with 1500 ml, 1.36% glucose PD solution was \n used. A small volume of dialysate was drained hourly to avoid overfill. An icodextrin 11- \n hour dwell (2000 ml, 7.5% Extraneal®), and a 4-hour PET (2000 ml, 2.27% glucose PD \n solution), were used as controls. Data expressed as mean ± SD, statistical analysis using \n one-way ANOVA, **p<0.01, ***p<0.001.","bbox":{"left":0.095142,"top":0.572482,"width":0.8019609999999999,"height":0.14476999999999995}},{"text":"Results \n The treatment time for icodextrin was 11.4±1.5 hours, for PET 4.1±0.1 hours, and for the \n Carry Life UF treatments 5.2±0.3 hours. Carry Life UF treatments generated increased \n ultrafiltration rates compared to icodextrin and PET (Figure a). The sodium removal rates \n with Carry Life UF treatments were also significantly increased compared to icodextrin and \n PET (Figure b). However, the total ultrafiltration volumes during Carry Life UF treatments \n were not significantly different compared to the icodextrin dwell (646±256, 739±312, \n 863±380, 595±239, ml/treatment for 11 g/h, 14 g/h, 20 g/h, and icodextrin, respectively). \n The ultrafiltration volume during PET was significantly lower than all other treatments","bbox":{"left":0.095142,"top":0.73454,"width":0.8089039999999998,"height":0.16190400000000005}},{"text":"57th ERA-EDTA Congress (Fully Virtual), June 6-9, 2020, Abstract P1160; and Nephrology Dialysis \n Transplantation, Volume 35, Issue Supplement_3, June 2020, gfaa142.P1160 (page 1484)","bbox":{"left":0.095142,"top":0.926154,"width":0.8070470000000001,"height":0.032982999999999874}}],"images_bbox":[{"left":0.095243,"top":0.042047,"width":0.227609,"height":0.032485}],"images_bbox_not_text_overlap":[{"left":0.095243,"top":0.042047,"width":0.227609,"height":0.032485}]}